NASDAQ:VCYT

Veracyte News Headlines

$36.14
-0.55 (-1.50 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$35.84
$37.58
50-Day Range
$32.94
$56.62
52-Week Range
$22.69
$86.03
Volume653,604 shs
Average Volume939,948 shs
Market Capitalization$2.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.73

Veracyte (NASDAQ VCYT) News Headlines Today

SourceHeadline
Veracyte (NASDAQ:VCYT) Lowered to "D+" at TheStreetVeracyte (NASDAQ:VCYT) Lowered to "D+" at TheStreet
marketbeat.com - May 28 at 7:11 AM
Veracyte (NASDAQ:VCYT) Shares Gap Up to $35.52Veracyte (NASDAQ:VCYT) Shares Gap Up to $35.52
americanbankingnews.com - June 10 at 12:06 PM
Veracyte (NASDAQ:VCYT) - Veracyte: Return On Capital Employed Insights - BenzingaVeracyte (NASDAQ:VCYT) - Veracyte: Return On Capital Employed Insights - Benzinga
benzinga.com - June 10 at 8:38 AM
Moving Average Crossover Alert: Veracyte (VCYT) - Yahoo FinanceMoving Average Crossover Alert: Veracyte (VCYT) - Yahoo Finance
finance.yahoo.com - June 9 at 9:11 AM
Moving Average Crossover Alert: Veracyte (VCYT)Moving Average Crossover Alert: Veracyte (VCYT)
finance.yahoo.com - June 9 at 9:11 AM
Form 8-K/A VERACYTE, INC. For: Jun 01 - StreetInsider.comForm 8-K/A VERACYTE, INC. For: Jun 01 - StreetInsider.com
streetinsider.com - June 8 at 6:42 PM
Veracyte: Tumultuous Times - Seeking AlphaVeracyte: Tumultuous Times - Seeking Alpha
seekingalpha.com - June 6 at 2:04 PM
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder - Business WireVeracyte Receives Final Medicare Coverage Policies for Decipher Bladder - Business Wire
businesswire.com - June 4 at 1:40 PM
Veracyte Receives Final Medicare Coverage Policies for Decipher BladderVeracyte Receives Final Medicare Coverage Policies for Decipher Bladder
finance.yahoo.com - June 4 at 1:40 PM
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences - Yahoo FinanceCORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - June 2 at 11:59 PM
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor ConferencesCORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
finance.yahoo.com - June 2 at 6:58 PM
Accenture To Buy French EPM Solutions Consulting Company NellArmonia; Terms Not Disclosed - NasdaqAccenture To Buy French EPM Solutions Consulting Company Nell'Armonia; Terms Not Disclosed - Nasdaq
nasdaq.com - June 2 at 12:00 AM
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx AcquisitionVeracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition
finance.yahoo.com - June 1 at 7:00 PM
Form 8-K VERACYTE, INC. For: Jun 01 - StreetInsider.comForm 8-K VERACYTE, INC. For: Jun 01 - StreetInsider.com
streetinsider.com - June 1 at 1:59 PM
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition - BenzingaVeracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition - Benzinga
benzinga.com - June 1 at 1:59 PM
Veracyte (NASDAQ:VCYT) Stock Price Down 5.3%Veracyte (NASDAQ:VCYT) Stock Price Down 5.3%
americanbankingnews.com - June 1 at 1:10 PM
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth - Business WireVeracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth - Business Wire
businesswire.com - June 1 at 8:58 AM
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics GrowthVeracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
finance.yahoo.com - June 1 at 8:58 AM
Veracyte (NASDAQ:VCYT) Rating Reiterated by William BlairVeracyte (NASDAQ:VCYT) Rating Reiterated by William Blair
americanbankingnews.com - May 27 at 9:08 AM
Veracyte to Present at Upcoming Investor Conferences - Business WireVeracyte to Present at Upcoming Investor Conferences - Business Wire
businesswire.com - May 26 at 6:07 PM
Veracyte RNA-sequencing test can aid in targeted treatments for thyroid cancer - Seeking AlphaVeracyte RNA-sequencing test can aid in targeted treatments for thyroid cancer - Seeking Alpha
seekingalpha.com - May 26 at 1:06 PM
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA SamplesVeracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
finance.yahoo.com - May 26 at 1:06 PM
Veracyte provides additional data on benefit of prostate cancer diagnostic test - Seeking AlphaVeracyte provides additional data on benefit of prostate cancer diagnostic test - Seeking Alpha
seekingalpha.com - May 25 at 12:08 PM
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic ClassifierVeracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
finance.yahoo.com - May 25 at 12:08 PM
Veracyte (NASDAQ:VCYT) Price Target Cut to $55.00Veracyte (NASDAQ:VCYT) Price Target Cut to $55.00
americanbankingnews.com - May 24 at 10:28 AM
Veracyte, Inc. (NASDAQ:VCYT) Expected to Announce Earnings of -$0.25 Per ShareVeracyte, Inc. (NASDAQ:VCYT) Expected to Announce Earnings of -$0.25 Per Share
americanbankingnews.com - May 23 at 11:18 AM
First Week of July 16th Options Trading For Veracyte (VCYT) - NasdaqFirst Week of July 16th Options Trading For Veracyte (VCYT) - Nasdaq
nasdaq.com - May 21 at 2:53 PM
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection - Business WireVeracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection - Business Wire
businesswire.com - May 19 at 7:19 PM
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer DetectionVeracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
finance.yahoo.com - May 19 at 7:19 PM
Veracyte (NASDAQ:VCYT) Price Target Lowered to $55.00 at Truist SecuritiesVeracyte (NASDAQ:VCYT) Price Target Lowered to $55.00 at Truist Securities
americanbankingnews.com - May 18 at 12:10 PM
Veracyte (NASDAQ:VCYT) Price Target Cut to $45.00Veracyte (NASDAQ:VCYT) Price Target Cut to $45.00
americanbankingnews.com - May 18 at 11:20 AM
Truist Cuts Veracyte (NASDAQ:VCYT) Price Target to $55.00Truist Cuts Veracyte (NASDAQ:VCYT) Price Target to $55.00
americanbankingnews.com - May 18 at 10:02 AM
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis - Business WireVeracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis - Business Wire
businesswire.com - May 14 at 6:52 PM
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD DiagnosisVeracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
finance.yahoo.com - May 14 at 6:52 PM
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy - Business WireVeracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy - Business Wire
businesswire.com - May 14 at 1:51 PM
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic BiopsyVeracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
finance.yahoo.com - May 14 at 1:51 PM
Veracyte (VCYT) Shares Cross Below Book Value - NasdaqVeracyte (VCYT) Shares Cross Below Book Value - Nasdaq
nasdaq.com - May 14 at 8:51 AM
Veracyte Stock Is Estimated To Be Significantly Overvalued - Yahoo FinanceVeracyte Stock Is Estimated To Be Significantly Overvalued - Yahoo Finance
finance.yahoo.com - May 14 at 8:51 AM
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) - NasdaqA Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) - Nasdaq
nasdaq.com - May 13 at 2:50 PM
US$72.50: Thats What Analysts Think Veracyte, Inc. (NASDAQ:VCYT) Is Worth After Its Latest Results - Yahoo FinanceUS$72.50: That's What Analysts Think Veracyte, Inc. (NASDAQ:VCYT) Is Worth After Its Latest Results - Yahoo Finance
finance.yahoo.com - May 13 at 2:50 PM
US$72.50: Thats What Analysts Think Veracyte, Inc. (NASDAQ:VCYT) Is Worth After Its Latest ResultsUS$72.50: That's What Analysts Think Veracyte, Inc. (NASDAQ:VCYT) Is Worth After Its Latest Results
finance.yahoo.com - May 13 at 9:46 AM
Veracyte (NASDAQ:VCYT) - Expert Ratings for Veracyte - BenzingaVeracyte (NASDAQ:VCYT) - Expert Ratings for Veracyte - Benzinga
benzinga.com - May 11 at 10:49 AM
Veracyte Announces First Quarter 2021 Financial Results - Business WireVeracyte Announces First Quarter 2021 Financial Results - Business Wire
businesswire.com - May 11 at 10:49 AM
Can the Uptrend Continue for Encore Wire Corp (WIRE)? - NasdaqCan the Uptrend Continue for Encore Wire Corp (WIRE)? - Nasdaq
nasdaq.com - May 11 at 12:39 AM
Veracyte, Inc. Announces CEO Succession Plan - Business WireVeracyte, Inc. Announces CEO Succession Plan - Business Wire
businesswire.com - May 10 at 7:34 PM
Veracytes (NASDAQ:VCYT) Wonderful 733% Share Price Increase Shows How Capitalism Can Build Wealth - Yahoo FinanceVeracyte's (NASDAQ:VCYT) Wonderful 733% Share Price Increase Shows How Capitalism Can Build Wealth - Yahoo Finance
finance.yahoo.com - May 4 at 7:46 PM
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress - Business WireVeracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress - Business Wire
businesswire.com - May 4 at 7:46 PM
Veracytes (NASDAQ:VCYT) Wonderful 733% Share Price Increase Shows How Capitalism Can Build WealthVeracyte's (NASDAQ:VCYT) Wonderful 733% Share Price Increase Shows How Capitalism Can Build Wealth
finance.yahoo.com - May 4 at 7:46 PM
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual CongressVeracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
finance.yahoo.com - May 4 at 7:46 PM
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO - Business WireVeracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO - Business Wire
businesswire.com - April 29 at 10:06 AM
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCOVeracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
finance.yahoo.com - April 29 at 10:06 AM
This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.